If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenedrive Regulatory News (GDR)

Share Price Information for Genedrive (GDR)

Share Price is delayed by 15 minutes
Get Live Data
1.30    0.00 (0.00%)
Bid:
1.25
Ask:
1.35
Spread: 0.10 (8.00%)
Market Cap: £20.87m
GDR Live PriceLast checked at - London Stock Exchange

Intraday Genedrive Share Chart

Block Listing Returns

31 May 2023 07:00

RNS Number : 0413B
Genedrive PLC
31 May 2023
 

 

genedrive plc

("genedrive" or the "Company")

 

Block Listing Returns

 

The Company confirms the block listing six monthly return for the period to 31 May 2023.

 

Name of applicant

genedrive plc

 

Name of scheme

2007 Share Option Scheme

 

Period of return:

From:

01 December 2022

To:

 31 May 2023

Balance of unallocated securities under scheme(s) from previous return:

139,226 shares

 

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

Nil

Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

7,500 shares

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

131,726 shares

 

 

In order to co-terminate future block listing returns the Company confirms the following returns for the two block listings granted earlier in the month.

 

Name of applicant

genedrive plc

 

Name of scheme

2017 Share Option Scheme

 

Period of return:

From:

19 May 2023

To:

 31 May 2023

Balance of unallocated securities under scheme(s) from previous return:

1,150,588 shares

 

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

Nil

Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

Nil

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

1,150,588 shares

 

 

Name of applicant

genedrive plc

 

Name of scheme

Unapproved Share Option Scheme

 

Period of return:

From:

19 May 2023

To:

 31 May 2023

Balance of unallocated securities under scheme(s) from previous return:

2,668,144 shares

 

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

Nil

Less:  Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

Nil

Equals:  Balance under scheme(s) not yet issued/allotted at end of period:

2,668,144 shares

 

Name of contact:

Russ Shaw CFO

Telephone number of contact:

+44 (0)161 989 0245

 

For enquires:

 

genedrive plc

+44 (0)161 989 0245

David Budd: CEO / Russ Shaw: CFO

Peel Hunt LLP (Nominated Adviser and Joint Broker)

+44 (0)20 7418 8900

James Steel / Oliver Duckworth

finnCap (Joint Broker)

+44 (0)20 7220 500

Geoff Nash / George Dollemore / Nigel Birks / Alice Lane

Walbrook PR Ltd (Media Relations & Investor Relations)

+44 (0)20 7933 8780 or genedrive@walbrookpr.com

Paul McManus / Anna Dunphy

+44 (0)7980 541 893 / +44 (0)7876 741 001

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BLRFLFILETIIVIV
Date   Source Headline
27th Jul 20177:00 amRNS$1.4m Funding from US Department of Defense
13th Jul 20177:00 amRNSTrading Update
11th Apr 20177:00 amRNSHep C data presentation at EASL
5th Apr 201712:39 pmRNSDirector/PDMR Shareholding - Replacement
5th Apr 201711:17 amRNSDirector/PDMR Shareholding
30th Mar 20177:00 amRNSInterim Results
27th Mar 20177:00 amRNSHCV Assay submitted for CE IVD Certification
24th Mar 20177:00 amRNSNotice of Interim Results
8th Mar 20177:00 amRNSSuccessful Clinical Results - Genedrive HCV Assay
20th Feb 20177:00 amRNSDirector/PDMR Shareholding
6th Feb 20175:53 pmRNSHoldings in Company
27th Jan 20177:00 amRNSTrading Update
16th Jan 20177:00 amRNSUpdate on US Department of Defense Programme
23rd Dec 201610:48 amRNSDirector/PDMR Shareholding
30th Nov 20162:16 pmRNSResult of AGM
29th Nov 20167:00 amRNSUpdate on CFO Appointment
17th Nov 20167:00 amRNSCE-IVD Certification for Human Genotyping Test
11th Nov 20165:47 pmRNSNotice of AGM
11th Oct 20167:00 amRNSPreliminary Results for the year end 30 June 2016
21st Sep 20167:00 amRNSNotice of Preliminary Results
21st Sep 20167:00 amRNSAppointment of Chief Financial Officer
10th Aug 20167:00 amRNSGenedrive Assay used in STOP-HCV-1 Clinical Trial
2nd Aug 20167:00 amRNSTrading Update
29th Jul 20165:58 pmRNSTotal Voting Rights
25th Jul 20167:00 amRNSRe change of name, TIDM and website address
14th Jul 20163:56 pmRNSHolding(s) in Company
14th Jul 20168:19 amRNSDirector/PDMR Shareholding
14th Jul 20168:18 amRNSHolding(s) in Company
13th Jul 20162:49 pmRNSHolding(s) in Company
12th Jul 20169:05 amRNSDirector/PDMR Shareholding
11th Jul 201611:34 amRNSResult of General Meeting and Change of Name
23rd Jun 20164:54 pmRNSPosting of Shareholder Circular
23rd Jun 20167:00 amRNSProposed Placing and Amendment to GHIF Bond
7th Jun 20167:00 amRNSBusiness Update
3rd May 20167:00 amRNSSuccessful Clinical Trial of Genedrive®
18th Apr 20167:00 amRNSEpistem Begins Full Commercial Launch of Genedrive
7th Apr 20164:54 pmRNSDirector/PDMR Shareholding
31st Mar 20167:00 amRNSInterim Results
21st Mar 20167:42 amRNSFunding award from US Department of Defense
19th Feb 20167:00 amRNSUpdate on CEO Appointment
18th Feb 20167:00 amRNSAnnounces Successful Assessment of Genedrive
13th Jan 20167:00 amRNSEpistem Appoints David Budd as CEO
16th Dec 20152:18 pmRNSDirector/PDMR Shareholding
16th Dec 20152:11 pmRNSResult of AGM
26th Nov 20154:41 pmRNSHolding(s) in Company
24th Nov 20153:28 pmRNSNotice of AGM
24th Nov 20152:07 pmRNSHolding(s) in Company
28th Oct 20157:00 amRNSPreliminary Results for year ended 30 June 2015
26th Oct 20157:00 amRNSEpistem Holdings Plc - Board Change
20th Oct 20157:00 amRNSNotice of Preliminary Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.